Clinical Trials in Baltimore

Showing 2641-2660 of 11,213 trials

Active Not RecruitingPhase 2< 1 mile

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

NCT04098081

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma

Advanced Pancreatic Cancer

University of Maryland, Baltimore15 participantsStarted Dec 2019

Baltimore, Maryland, United States

RECRUITINGEARLY Phase 1< 1 mile

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304

This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab may enhance the effectiveness of a standard chemotherapy (DA-EPOCH) in patients with plasmablastic lymphoma.

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more

AIDS Malignancy Consortium15 participantsStarted May 2021

Miami, Florida, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +5 more locations

1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Find Trials by Condition in Baltimore

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Using Technology to Track Pain and Pain-related Outcomes

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)

Vaginal Ecosystem and Network in the United States Study

Plant-Based Dietary Intervention in Type 2 Diabetes-2

Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women

Study of ASN51 in Adults With Early Alzheimer's Disease

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Gluten Technology and Education for Celiac Health

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

Cough Reduction in IPF With Nalbuphine ER

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)